Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2023
Reporting Period: Event-specific report regarding corporate action approved on November 14, 2023.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a corporate capital structure adjustment.
Material Changes
The Board of Directors approved a 1-for-40 reverse stock split affecting both Class A and Class B common stock. Key details include:
- Effective Date: 4:01 p.m. Eastern Time on November 20, 2023.
- Trading Resumption: Post-split trading expected to begin on November 21, 2023, under CUSIP number 91835204.
- Fractional Shares: No fractional shares will be issued; entitlements will be rounded up to the nearest whole share.
- Ownership Percentage: Stockholder ownership percentages will remain unchanged, subject to rounding adjustments.
Outlook, Risks, and Management Commentary
Purpose of Action: The reverse stock split is intended to regain compliance with the Nasdaq Capital Market requirement for a minimum $1.00 per share closing price.
Risks and Uncertainties: The filing includes a forward-looking statement disclaimer. There is no guarantee that the reverse stock split will result in the Company regaining compliance with Nasdaq listing rules. Actual results may differ materially from expectations due to risks outlined in the Company's Form 10-K and subsequent filings.
Investor Verification Checklist
- Verify the effective time of the reverse stock split (November 20, 2023, at 4:01 p.m. ET).
- Confirm the new CUSIP number (91835204) for post-split trading.
- Review the Company's subsequent filings to determine if the reverse split successfully restored Nasdaq listing compliance.
- Check for any updates regarding the treatment of fractional shares if specific broker-dealer policies differ from the rounding-up provision.